Corcept Q1 Loss, Revenue Miss Underscore Near-Term Headwinds

What happened

Corcept Therapeutics reported a Q1 loss of $0.3 per share, in line with expectations but down from a $0.17 profit a year ago, and missed revenue estimates. This reinforces concerns flagged in our prior report about Korlym erosion from authorized generic competition and payer pressure, which could accelerate. Despite a profitable Cushing's franchise and a late-stage relacorilant catalyst, the current P/E of ~73x leaves minimal margin of safety, and this quarter's results highlight the fragility of near-term earnings power.

Implication

Investors should watch for continued Korlym revenue erosion and await the relacorilant FDA decision. If approval comes with a broad label, the thesis could upgrade, but Q1 loss suggests increasing downside risk. Maintain HOLD with tight stop-losses until binary catalysts resolve.

Thesis delta

The Q1 loss and revenue miss shift our thesis from neutral to slightly bearish, as it confirms that Korlym's authorized generic and payer dynamics are already weighing on results. While the relacorilant catalyst remains, the elevated valuation now looks less justified, reducing the probability of an upgrade and increasing SELL risk if the pipeline disappoints.